Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India

Bibliographic Details
Main Author:	The Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-04-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976243/?tool=EBI

Similar Items

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
by: Sakib Burza, et al.
Published: (2014-01-01)

Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India.
Published: (2014-04-01)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
by: The Staff
Published: (2014-04-01)

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014-01-01)

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014-01-01)

Correction: Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India.
Published: (2014-04-01)

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
by: Sakib Burza, et al.
Published: (2014-08-01)

Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.
by: Emiliano Lucero, et al.
Published: (2015-04-01)

Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case
by: Maria Antonia Ferreira Gomes, et al.

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
by: Gert-Jan Wijnant, et al.
Published: (2018-08-01)

Single-dose liposomal amphotericin B for visceral leishmaniasis
by: Nilima A Kshirsagar
Published: (2014-04-01)

Different liposomal amphotericin B formulations for visceral leishmaniasis
by: Thomas P C Dorlo, et al.
Published: (2014-08-01)

Single-dose liposomal amphotericin B (AmBisome<sup>®</sup>) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
by: Smith Peter G, et al.
Published: (2011-03-01)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
by: Charles Abongomera, et al.
Published: (2018-05-01)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016-01-01)

Visceral Leishmaniasis in Rural Bihar, India
by: Epco Hasker, et al.
Published: (2012-10-01)

Different liposomal amphotericin B formulations for visceral leishmaniasis–Author's reply
by: Nilima Kshirsagar
Published: (2014-08-01)

Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis
by: Prabhat Kumar Sinha, et al.
Published: (2014-01-01)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
by: Andrew A Voak, et al.
Published: (2021-03-01)

Ambisome as first line treatment of a child with ALL associated with the relapse of leishmaniasis
by: D.B. Alia, et al.
Published: (2014-04-01)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
by: Md Golam Hasnain, et al.
Published: (2018-12-01)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
by: Ermias Diro, et al.
Published: (2019-01-01)

Liposomal amphotericin B and leishmaniasis: Dose and response
by: Shyam Sundar, et al.
Published: (2010-01-01)

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: A possible challenge to elimination program in India
by: VNR Das, et al.
Published: (2013-01-01)

Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
by: Vishal Goyal, et al.
Published: (2020-07-01)

Visceral Leishmaniasis in Children in Southern Turkey: Evaluation of Clinical and Laboratory Findings and Liposomal Amphotericin B Treatment
by: Barbaros Şahin Karagün, et al.
Published: (2019-06-01)

Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008.
by: Paritosh Malaviya, et al.
Published: (2011-03-01)

Relapse of Visceral Leishmaniasis in an HIV-Infected Patient Successfully Treated with a Combination of Miltefosine and Amphotericin B
by: Shauna McQuarrie, et al.
Published: (2015-01-01)

Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India.
by: Caroline A Bulstra, et al.
Published: (2018-12-01)

Impact of ASHA training on active case detection of visceral leishmaniasis in Bihar, India.
by: Vidya Nand Ravi Das, et al.
Published: (2014-05-01)

Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India
by: Sarah Jervis, et al.
Published: (2017-12-01)

A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India
by: Vidya N, et al.
Published: (2008-12-01)

Subclinical tumor lysis-like syndrome during treatment of visceral leishmaniasis with low-dose intermittent liposomal amphotericin B
by: Georgiadou Sarah, et al.
Published: (2012-06-01)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India.
by: Michaela Fakiola, et al.
Published: (2019-08-01)

Mathematical modelling of the use of insecticide-treated nets for elimination of visceral leishmaniasis in Bihar, India
by: Anna K. Fortunato, et al.
Published: (2021-06-01)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
by: Ridwanur Rahman, et al.
Published: (2017-05-01)

Visceral Leishmaniasis with Endobronchial Involvement in an Immunocompetent Adult
by: Konstantinos Kotsifas, et al.
Published: (2011-01-01)

Visceral leishmaniasis with pleural effusion in an immunocompetent patient
by: Senjuti Dasgupta, et al.
Published: (2014-01-01)

Introducing Single Dose Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis in Rural Bangladesh: Feasibility and Acceptance to Patients and Health Staff
by: Eva-Maria Maintz, et al.
Published: (2014-01-01)

Mannosylated nanoparticles for targeted delivery of amphotericin B towards visceral leishmaniasis
by: Daniela Filipa dos Santos Barros
Published: (2019)